Timing between rituximab and 90Y-ibritumomab tiuxetan in pts with Non-Hodgkin's lymphoma does not affect clinical outcomes.

被引：0
|
作者：
Friedman, Isaiah E.
Andreadis, Charalambos
Diangi, Yumi Taylor
Nasta, Sunita D.
Luger, Selina M.
Stadtmauer, Edward A.
Schuster, Stephen J.
机构：
[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4735
引用
收藏
页码：267B / 267B
页数：1
相关论文
共 50 条
  • [41] 90Y ibritumomab tiuxetan and rituximab for the treatment of relapsed or refractor), diffuse large B-cell non-Hodgkin's lymphoma.
    Buff, Michael S.
    Royer, Anna
    Ely, Pamela
    Grant, Barbara
    Parker, J. Anthony
    Joyce, Robin M.
    BLOOD, 2006, 108 (11) : 779A - 779A
  • [42] Registry of radioimmunotherapy: Analysis of outcomes of recurrent or refractory Non-Hodgkin Lymphoma patients treated with 90Y Ibritumomab tiuxetan
    Giraldo, P.
    Codina, J. Gomez
    ANNALS OF ONCOLOGY, 2008, 19 : 208 - 208
  • [43] Registry of radioimmunotherapy: Analysis of outcomes of recurrent or refractory non-Hodgkin lymphoma patients treated with 90Y Ibritumomab tiuxetan
    Giraldo, Pilar
    Codina, Jose Gomez
    Feixeira, Adriana
    Hernando, Teresa
    Tisaire, Jose Luis
    BLOOD, 2007, 110 (11) : 190B - 190B
  • [44] Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma
    Lossos, Izidore S.
    Reis, Isildinha M.
    Rosenblatt, Joseph D.
    Alderuccio, Juan Pablo
    LEUKEMIA & LYMPHOMA, 2020, 61 (13) : 3234 - 3238
  • [45] Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
    Witzig, TE
    Flinn, IW
    Gordon, LI
    Emmanouilides, C
    Czuczman, MS
    Saleh, MN
    Cripe, L
    Wiseman, G
    Olejnik, T
    Multani, PS
    White, CA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) : 3262 - 3269
  • [46] JUT with 90Y Ibritumomab Tiuxetan in Agressive Non-Hodgkin Lymphoma. Evaluation of Recent Outcomes in a Single Institution
    Montes, Anel
    Andrade, Ma
    Murillo, Ilda
    Lopez-Gomez, Luis
    Baringo, Teresa
    Giraldo, Pilar
    BLOOD, 2012, 120 (21)
  • [47] Zevalin - Ibritumomab tiuxetan - IDEC - Radiommunotherapeutic for non-Hodgkin's lymphoma
    不详
    FORMULARY, 2002, 37 (04) : 170 - 170
  • [48] Localization of yttrium 90 ibritumomab tiuxetan (90Y IT) in patients with CD20+ non-Hodgkin's lymphoma (NHL).
    Jacobs, SA
    Swerdlow, SA
    Avril, N
    Vidnovic, N
    Foon, KA
    Harrison, AM
    McCarty, KS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 177S - 177S
  • [49] Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma:: Combined data from 4 clinical trials
    Wiseman, GA
    Kornmehl, E
    Leigh, B
    Erwin, WD
    Podoloff, DA
    Spies, S
    Sparks, RB
    Stabin, MG
    Witzig, T
    White, CA
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (03) : 465 - 474
  • [50] Imaging with 111In-Ibritumomab and 18F-FDG PET/CT in 90Y-Ibritumomab radioimmunotherapy of non-Hodgkin's lymphoma
    Banzo, I.
    Martinez-Rodriguez, I.
    Quirce, R.
    Jimenez-Bonilla, J.
    Sainz-Esteban, A.
    Barragan, J.
    Portilla-Quattrociocchi, H.
    Medina-Quiroz, P.
    Carril, J.
    Marques Valdecilla, H. U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
12345